SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 196.08-0.2%Jan 15 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (10423)10/30/1997 6:49:00 PM
From: squetch  Read Replies (1) of 32384
 
There is a 5.1.95 WSJ article on psoriasis indication. Says there was a Nature Medicine article that maybe somebody could dig up?

IN the study 4/10 psoriasis subjects had "striking" reduction of scaliness, itching and other symptoms, w/ a fflicted patches of their seeming return to normal. Another 4 had moderate improvement.

SRGN's drug knocks out certain immune cells, and the patients w/ the most improvement were ones in which abnormal immune-cell activity in the skin was most reduced. The study's results are the stronges evidence that misguided immune attack underlie psoriasis, Dr. Krueger said. He indicated the drug could alleviate psoriasis "for a considerable time," perhaps many months. ... The drugs selective punch to the immune system isn't expected to cause serious side effects. The main effect appeared to be flu-like symptoms.

I have some stuff that I'll try to post later.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext